Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Multi-Centric, Randomised, Open-label, Parallel-Group Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer

NCT00444639 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT00444639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00444639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Multi-Centric, Randomised, Open-label, Parallel-Group Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer
Lead sponsor
Ipsen
Phase
Phase 2
Overall status
Terminated
Start date
February 28, 2007
Completion date
June 30, 2008
Enrollment
25 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer